前列地尔联合纤溶酶治疗内听动脉闭塞综合征临床评价

Observation on Clinical Efficacy of Alprostadil Combined with Plasmin in Treating Internal Auditory Artery Occlusion Syndrome

目的探讨前列地尔联合纤溶酶治疗内听动脉闭塞综合征的临床疗效。方法选取内听动脉闭塞综合征患者88例,随机均分为试验组和对照组。两组均给予常规基础治疗,试验组加用前列地尔和纤溶酶。比较两组患者的临床疗效,检测治疗前后脑干听觉诱发电位、全血比黏度和血小板聚集率,记录不良反应发生情况。结果试验组治疗总有效率为95.45%,高于对照组的77.27%（P〈0.05）。治疗后,除峰间潜伏期（IPL）Ⅰ-Ⅲ无明显变化外,两组IPLⅢ-Ⅴ,IPLⅠ-Ⅴ均较治疗前有显著改善,试验组优于对照组（P〈0.05）,组间比较,潜伏期（PL）Ⅰ差异无统计学意义（P〉0.05）,PLⅢ,PLⅤ试验组均好于对照组（P〈0.05）。治疗后,两组患者全血比黏度、血小板聚集率均较治疗前有显著改善,且试验组改善程度优于对照组（P〈0.05）。治疗过程中,均未出现影响治疗的不良反应。结论前列地尔联合纤溶酶治疗内听动脉闭塞综合征的临床效果显著,不良反应少,值得临床推广。

Objective To investigate the clinical efficacy of alprostadil combined with plasmin in treating internal auditory artery occlusion syndrome.Methods 88 cases of internal auditory artery occlusion syndrome were chosen and randomly divided into the control group and experimental group.The two groups were given the routine basic therapy,whereas the experimental group was added with alprostadil and plasmin.The clinical effects were compared between the two groups.The brain stem auditory evoked potential,whole blood specific viscosity and platelet aggregation rate were detected before and after treatment.The occurrence situation of adverse reactions was recorded.Results The total effective rate in the experimental group was 95.45%,which washigher than 77.27% in the control group,the difference was statistically significant（P〈0.05）.Except for no obvious change in IPL Ⅰ~ Ⅲ,the other indexes in the two groups were significantly improved compared with before treatment（P〈0.05）; the difference in PL Ⅰ between the two groupshad no statistical significance（P〉0.05）,the other indexes in the experimental group were better than those in the control group（P〈0.05）.The whole blood specific viscosity and platelet aggregation rate after treatment in the two groups were obviously improved compared with before treatment,moreover the improvement degree in the experimental group was greater than that in the control group with statistical difference（P〈0.05）.Conclusion Alprostadil combined with plasminhas obvious effect and less adverse reactions for treating internal auditory artery occlusion syndrome and is worthy of being promoted in clinic.